Clinical Trials
177 trialsEvaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
M.D. Anderson Cancer Center
ALPHA3
Allogene Therapeutics
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Amgen
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
ROTATE
Yale University
MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma
University of Nebraska
PREeMPT
Medical College of Wisconsin
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Dana-Farber Cancer Institute
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Amgen
Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
Weill Medical College of Cornell University
PREDICT-RD
UNC Lineberger Comprehensive Cancer Center
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
Dartmouth-Hitchcock Medical Center
CASSIOPEIA
Novartis
VEN+IDAC vs IDAC in AML
Guangdong Second Provincial General Hospital
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
Stanford University
PALAVY
Abramson Cancer Center at Penn Medicine
Motixafortide for MRD Sensitization in AML
Washington University School of Medicine
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Masonic Cancer Center, University of Minnesota
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Eastern Cooperative Oncology Group
DEL-MRD-CHID
Fudan University
AlloNK1
Singapore General Hospital
FLAMINGO-01
Greenwich LifeSciences, Inc.
Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome
City of Hope Medical Center
EMAT
Medical College of Wisconsin
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
Second Xiangya Hospital of Central South University
Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
MiRaDoR
MedSIR
Relugolix + Enzalutamide Study in High-Risk Prostate Cancer
University of Oklahoma
LAL-2025
PETHEMA Foundation
CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
Peking University People's Hospital
Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial
Sun Yat-sen University
Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Dana-Farber Cancer Institute
A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)
Memorial Sloan Kettering Cancer Center
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
Columbia University
Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant
University of Chicago
Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC
Tongji Hospital
Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
UNC Lineberger Comprehensive Cancer Center
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
University of Alabama at Birmingham
CELERITY
Centre Henri Becquerel
FIL_GAZEBO
Fondazione Italiana Linfomi - ETS
BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
Ruijin Hospital
S101MRD
Peking University People's Hospital
Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study
Nanfang Hospital, Southern Medical University
MRD-ATLAS
Shanghai Zhongshan Hospital
NeckTAR-IN
Centre Jean Perrin
ICLL07GAI
French Innovative Leukemia Organisation